Arbutus Biopharma (ABUS) Net Income towards Common Stockholders (2013 - 2026)

Arbutus Biopharma has disclosed Net Income towards Common Stockholders across 14 years of filings, most recently posting $169.7 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $169.7 million, up 791.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $160.0 million (up 309.11% YoY), and the FY2025 annual result was -$34.2 million, up 51.1% from the prior year.
• Net Income towards Common Stockholders came in at $169.7 million for Q1 2026 at Arbutus Biopharma, up from -$4.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $169.7 million in Q1 2026 to a low of -$24.5 million in Q1 2025.
• The 5-year median for Net Income towards Common Stockholders is -$17.1 million (2023), against an average of -$4.5 million.
• Across the five-year window, Net Income towards Common Stockholders slumped 37.33% in 2025 and surged 791.83% in 2026, its largest moves.
• Arbutus Biopharma's Net Income towards Common Stockholders stood at -$21.9 million in 2022, then advanced by 11.95% to -$19.3 million in 2023, then surged by 35.28% to -$12.5 million in 2024, then soared by 64.55% to -$4.4 million in 2025, then jumped by 3929.97% to $169.7 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $169.7 million (Q1 2026), -$4.4 million (Q4 2025), and -$7.7 million (Q3 2025), per Business Quant data.